ELI LILLY AND COMPANY Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
ELI LILLY AND COMPANY (LLY) reported Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents of $15.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Change in Cash
us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-05
- ELI LILLY AND COMPANY effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2026-03-31 was $67.00M, a 49.24% decline year-over-year.
- ELI LILLY AND COMPANY effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2025-03-31 was $132.00M.
- ELI LILLY AND COMPANY effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2024-03-31 was -$35.50M, a 243.15% decline year-over-year.
- ELI LILLY AND COMPANY effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2023-03-31 was $24.80M, a 26.19% decline year-over-year.
- ELI LILLY AND COMPANY effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2025 was $372.00M.
- ELI LILLY AND COMPANY effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2024 was -$297.00M, a 275.74% decline from fiscal 2023.
- ELI LILLY AND COMPANY effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2023 was $169.00M.
- ELI LILLY AND COMPANY effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2022 was -$167.60M.
| Period end | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3 month as first filed | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6 month as first filed | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $15.00M 10-Q · filed 2026-08-05 | ||||||
| 2026-03-31 | $67.00M 10-Q · filed 2026-04-30 | ||||||
| 2025-12-31 | $372.00M 10-K · filed 2026-02-12 | ||||||
| 2025-09-30 | $439.10M 10-Q · filed 2025-10-30 | ||||||
| 2025-06-30 | $407.00M 10-Q · filed 2026-08-05 | $407.40M 10-Q · filed 2025-08-07 | |||||
| 2025-03-31 | $132.00M 10-Q · filed 2026-04-30 | $131.90M 10-Q · filed 2025-05-01 | |||||
| 2024-12-31 | -$297.00M 10-K · filed 2026-02-12 | -$296.70M 10-K · filed 2025-02-19 | |||||
| 2024-09-30 | $131.80M 10-Q · filed 2025-10-30 | ||||||
| 2024-06-30 | -$95.10M 10-Q · filed 2025-08-07 | ||||||
| 2024-03-31 | -$35.50M 10-Q · filed 2025-05-01 | ||||||
| 2023-12-31 | $169.00M 10-K · filed 2026-02-12 | $168.60M 10-K · filed 2024-02-21 | |||||
| 2023-09-30 | $39.30M 10-Q · filed 2024-10-30 | ||||||
| 2023-06-30 | $34.00M 10-Q · filed 2024-08-08 | ||||||
| 2023-03-31 | $24.80M 10-Q · filed 2024-04-30 | ||||||
| 2022-12-31 | -$167.60M 10-K · filed 2025-02-19 | ||||||
| 2022-09-30 | -$39.40M 10-Q · filed 2023-11-02 | ||||||
| 2022-06-30 | -$35.80M 10-Q · filed 2023-08-08 | ||||||
| 2022-03-31 | $33.60M 10-Q · filed 2023-04-27 | ||||||
| 2021-12-31 | -$205.70M 10-K · filed 2024-02-21 | ||||||
| 2021-09-30 | $15.00M 10-Q · filed 2022-11-01 | ||||||
| 2021-06-30 | -$1.60M 10-Q · filed 2022-08-04 | ||||||
| 2021-03-31 | -$10.20M 10-Q · filed 2022-04-29 | ||||||
| 2020-12-31 | $216.00M 10-K · filed 2023-02-22 | ||||||
| 2020-09-30 | $3.80M 10-Q · filed 2021-10-27 | ||||||
| 2020-06-30 | -$12.40M 10-Q · filed 2021-08-03 | ||||||
| 2020-03-31 | -$66.70M 10-Q · filed 2021-04-30 | ||||||
| 2019-12-31 | -$89.90M 10-K · filed 2022-02-23 | ||||||
| 2019-09-30 | -$54.90M 10-Q · filed 2020-10-28 | ||||||
| 2019-06-30 | $64.90M 10-Q · filed 2020-07-31 | ||||||
| 2019-03-31 | $37.80M 10-Q · filed 2020-05-01 | ||||||
| 2018-12-31 | -$63.60M 10-K · filed 2021-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |